Melur Ramakrishnaiah

Array ( [id] => 11888031 [patent_doc_number] => 09758583 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-09-12 [patent_title] => 'Anti-CTLA-4 antibodies' [patent_app_type] => utility [patent_app_number] => 15/486468 [patent_app_country] => US [patent_app_date] => 2017-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 23 [patent_no_of_words] => 26013 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15486468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12001895 [patent_doc_number] => 20170306050 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'COMPOSITIONS AND METHODS FOR TREATING CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES' [patent_app_type] => utility [patent_app_number] => 15/482452 [patent_app_country] => US [patent_app_date] => 2017-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 42861 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15482452 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11873625 [patent_doc_number] => 09745382 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2017-08-29 [patent_title] => 'Bispecific anti-HER2 antibody' [patent_app_type] => utility [patent_app_number] => 15/461732 [patent_app_country] => US [patent_app_date] => 2017-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 21 [patent_no_of_words] => 13365 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15461732 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16312643 [patent_doc_number] => 20200291381 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => PRODUCTION OF ANTIGEN-SPECIFIC T-CELLS [patent_app_type] => utility [patent_app_number] => 16/084121 [patent_app_country] => US [patent_app_date] => 2017-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14107 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -70 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16084121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12001857 [patent_doc_number] => 20170306012 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'MONOCLONAL ANTIBODIES TO PROGASTRIN AND THEIR USES' [patent_app_type] => utility [patent_app_number] => 15/451275 [patent_app_country] => US [patent_app_date] => 2017-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 33788 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15451275 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12151538 [patent_doc_number] => 20180022802 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-25 [patent_title] => 'MONOCLONAL ANTIBODIES TO PROGASTRIN AND THEIR USES' [patent_app_type] => utility [patent_app_number] => 15/451268 [patent_app_country] => US [patent_app_date] => 2017-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 33807 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15451268 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13251215 [patent_doc_number] => 10138287 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-11-27 [patent_title] => Uterine cancer treatments [patent_app_type] => utility [patent_app_number] => 15/451167 [patent_app_country] => US [patent_app_date] => 2017-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 18 [patent_no_of_words] => 34459 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15451167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12001856 [patent_doc_number] => 20170306011 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'MONOCLONAL ANTIBODIES TO PROGASTRIN AND THEIR USES' [patent_app_type] => utility [patent_app_number] => 15/451253 [patent_app_country] => US [patent_app_date] => 2017-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 33803 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15451253 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11706262 [patent_doc_number] => 20170174761 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-22 [patent_title] => 'MONOCLONAL ANTIBODIES TO PROGASTRIN AND THEIR USES' [patent_app_type] => utility [patent_app_number] => 15/451280 [patent_app_country] => US [patent_app_date] => 2017-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 33780 [patent_no_of_claims] => 49 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15451280 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15193925 [patent_doc_number] => 10494441 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-03 [patent_title] => Anti-ERBB3 antibodies [patent_app_type] => utility [patent_app_number] => 15/448164 [patent_app_country] => US [patent_app_date] => 2017-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 30 [patent_no_of_words] => 24949 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15448164 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11936490 [patent_doc_number] => 20170240639 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-24 [patent_title] => 'ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY' [patent_app_type] => utility [patent_app_number] => 15/439386 [patent_app_country] => US [patent_app_date] => 2017-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 87116 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15439386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14883513 [patent_doc_number] => 10421783 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-24 [patent_title] => Prostate-specific membrane antigen (PSMA) targeting peptides [patent_app_type] => utility [patent_app_number] => 15/437248 [patent_app_country] => US [patent_app_date] => 2017-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 10084 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15437248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11649195 [patent_doc_number] => 20170145097 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR CD22' [patent_app_type] => utility [patent_app_number] => 15/424238 [patent_app_country] => US [patent_app_date] => 2017-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 23349 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15424238 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16125993 [patent_doc_number] => 10696738 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-30 [patent_title] => Anti-serum albumin binding variants [patent_app_type] => utility [patent_app_number] => 15/363223 [patent_app_country] => US [patent_app_date] => 2017-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 2 [patent_no_of_words] => 17388 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15363223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16321308 [patent_doc_number] => 10781264 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-22 [patent_title] => PSMA and CD3 bispecific T cell engaging antibody constructs [patent_app_type] => utility [patent_app_number] => 15/422661 [patent_app_country] => US [patent_app_date] => 2017-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 18 [patent_no_of_words] => 52425 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 187 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15422661 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11668511 [patent_doc_number] => 20170157231 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-08 [patent_title] => 'Therapeutic Cancer Vaccine' [patent_app_type] => utility [patent_app_number] => 15/410842 [patent_app_country] => US [patent_app_date] => 2017-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 7379 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15410842 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11821866 [patent_doc_number] => 20170210803 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-27 [patent_title] => 'TREATMENT OF CANCER WITH COMBINATIONS OF IMMUNOREGULATORY AGENTS' [patent_app_type] => utility [patent_app_number] => 15/411623 [patent_app_country] => US [patent_app_date] => 2017-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 17567 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15411623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11743979 [patent_doc_number] => 20170198051 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-13 [patent_title] => 'MULTIVALENT AND MULTISPECIFIC OX40-BINDING FUSION PROTEINS' [patent_app_type] => utility [patent_app_number] => 15/404167 [patent_app_country] => US [patent_app_date] => 2017-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 21168 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15404167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12983668 [patent_doc_number] => 20170343550 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-30 [patent_title] => NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 15/402081 [patent_app_country] => US [patent_app_date] => 2017-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27369 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15402081 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11979333 [patent_doc_number] => 20170283487 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS' [patent_app_type] => utility [patent_app_number] => 15/400618 [patent_app_country] => US [patent_app_date] => 2017-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 60719 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15400618 [rel_patent_id] =>[rel_patent_doc_number] =>)